$SIBN

Healthcare Alkermes ($ALKS) announced that it received notices of partial termination in respect of two license agreements with Janssen Pharmaceutica N.V., a subsidiary of Johnson & Johnson Acadia Pharmaceuticals Inc ($ACAD) 3Q EPS ($0.09) vs est. ($0.26) on sales $131.6Mm vs est. $127.8Mm, says narrows FY Nuplazid sales guide to $480-500Mm Castle Biosciences ($CSTL) 3Q EPS ($0.47) vs est. ($0.41) on revs $23.5Mm vs est. $23Mm; says on track to achieve FY total revs guide of $89-93Mm vs est. $91.9Mm Clover Health ($CLOV) Q3 revs $427.2M vs est. $413.1M, adj EBITDA ($102.3M) vs est. ($99.5M); sees FY revs $1.42B-$1.47B vs est. $1.44B Curaleaf holdings ($CURLF) Q3 revenue $317M vs est. $328.3M, adj EBITDA $71M vs est. $92.1M; remains on track to generate revenue within lower end of $1.2B-$1.3B annual guidance range; said the acquisition of Tryke Companies reported earlier today bolsters its position in NV, AZ, UT and will be immediately accretive to margins and cash flow Fluidigm Corp ($FLDM) 3Q EPS ($0.18) vs est. ($0.22) on revs $28.5Mm vs est. $30Mm; says undertaking review of various options including with regard to strategic alternatives Invitae Corporation ($NVTA) Q3 adj EPS ($0.81) vs est. ($0.71) on revenue $114.4M vs est. $126.5M driven by billable volume 296k (+89% YoY); now sees FY revenue $450M-$475M, from $475M-$500M and below est. $484.5M Mirati Therapeutics, Inc. ($MRTX) 3Q EPS ($1.55) vs est. ($2.89) on revs $71.8Mm Nevro Corp. ($NVRO) Q3 EPS loss ($1.44) vs. est. loss (-$0.87); Q3 rev $93.2M vs. est. $91.59M; sees Q4 revs $94M-$98M Oak Street Health, Inc. ($OSH) Q3 EPS loss (-$0.49) vs. est. loss (-$0.42); Q3 revs $388.7M vs. est. $356.7M; The Company cared for approximately 100,500 risk-based patients, representing 76% of its total patients; adjusted EBITDA was $(64.3M), compared to $(22.8M) YoY SI-BONE ($SIBN) Q3 EPS ($0.48) vs est. ($0.42) on revenue $22.3M vs est. $22.5M, lowered FY21 revenue view to $89M-$90M from $92M-$94M (vs est. $92.7M) as uncertainty surrounding Covid-19’s impact on elective procedures and healthcare infrastructure remains Shockwave Medical ($SWAV) Q3 EPS $0.05 vs. est. loss (-$0.06); Q3 revs $65.2M vs. est. $61.2M; sees FY21 revenue $227M-$228M vs. est. $223.43M, which represents 235% to 236% growth YoY SmileDirectClub, Inc. ($SDC) shares fall -23%; 3Q EPS ($0.23) vs est. ($0.13) on revs $138Mm vs est. $$181Mm; guides FY revs $630-650Mm vs est. $757Mm Tactile Systems ($TCMD) shares fell -12%; 3Q EPS ($0.17) vs est. $0.12 on revs $52.5Mm vs est. $57.4Mm; sees FY revs +9-10% or $203.5M-$206M from $216.3M-$224.5M, below est. +18.7% Merck ($MRK) said the U.S. government will buy 1.4 million additional courses of their COVID-19 pill, molnupiravir, for about $1 bln and that the U.S. has now committed to purchase a total of about 3.1 million courses of molnupiravir for about $2.2 billion Haemonetics ($HAE) Q2 adj EPS $0.60 vs. est. $0.61; Q2 revs $239.9M vs. est. $241.4M; lowers FY22 adj EPS view to $2.40-$2.65 from $2.60-$3.00 and narrows its FY22 revenue view to up 13%-17% from up 13%-18% Technology, Media & Telecom Bandwidth Inc. ($BAND) Q3 adj EPS $0.25 vs. est. $0.08; Q3 revs $130.6M vs. est. $125.3M; guides Q4 EPS loss (15c-11c) vs. est. loss (-$0.01); sees Q4 revs $115.7M-$120.7M vs. est. $125.5M 3D Systems ($DDD) 3Q adj EPS $0.08 vs est. $0.05 on revs $156.1Mm vs est. $144.8Mm; guides FY adj gr mgn 41-43% vs est. 42.7% Five9 Inc. ($FIVN) 3Q adj EPS $0.28 vs est. $0.23 on revs $154.3Mm vs est. $146.8Mm; guides 4Q revs $164.5-165.5mm vs est. $157.8Mm, sees 4Q adj EPS $0.36-0.37 vs est. $0.34; sees FY revs $$600.5-601.5Mm vs est. $585.2Mm and adj EPS $1.09-1.10 vs est. $1.02 Instructure Holdings, Inc. ($INST) 3Q EPS ($0.10) vs est. $0.14 on revs $107.2Mm vs est. $101.1Mm; sees 4Q revs $106.9-107.9Mm vs est. $104.1Mm; guides FY revs $401.7-402.7Mm vs est. $397.4Mm, sees FY adj EBITDA $143.6-144.6Mm vs est. $130Mm Luminar Technologies, Inc. ($LAZR) shares rise 50%; said at the NVIDIA GTC conference that its lidar solution has been selected to be part of the sensor suite in the NVIDIA DRIVE Hyperion autonomous vehicle reference platform. This AI vehicle computing platform accelerates development of autonomous consumer vehicles with planned production starting in 2024. New Relic ($NEWR) Q2 adj EPS loss (10c) vs. est. loss (13c); Q2 revs $196M vss. Est. $182.21M; cuts FY22 adj EPS loss view to (60c)-(54c) from (52c)-(49c) while boosts FY22 revenue view to $778M-$782M from $730M-$735M (est. $736.8M) National CineMedia ($NCMI) Q3 EPS loss (19c) vs. est. loss (13c); Q3 revs $31.7M vs. est. $41.24M; Q3 adjusted OIBDA improved to negative $8.2 million for the third quarter of 2021 from negative $11.2 million for the third quarter of 2020 Roblox ($RBLX) shares rise 29%; Q3 EPS (13c) vs est. (14c) on bookings $637.8M vs est. $636.5M, revenue $509.5M, avg DAUs 47.3M vs est. 46.6M, hours engaged 11.2B (+28% YoY), avg booking per DAU $13.49 Sanmina ($SANM) Q4 adj EPS $0.95 vs. est. $0.99; Q4 revs $1.64B vs. est. $1.7B; sees Q1 adj EPS 90c-$1.00 vs. est. $1.01; sees Q1 revs $1.6B-$1.7B below consensus $1.76B Square Space ($SQSP) Q3 EPS 4c vs est. 14c on revenue $201M vs est. $205.2M; sees Q4 revenue $203M-$206M vs est. $205.2M, raised annual revenue forecast to $780M-$783M from $772M-$780M (est. $778.4M) and unlevered FCF to $117M-$122M from $102M-$116M TripAdvisor ($TRIP) 3Q adj EPS $0.16 vs est. $0.24 on revs $303Mm vs est. $304.4Mm; avg monthly unique users on branded websites rose to about 76% of 2019 comparable period; says CEO will step down during 2022 Vuzix Corporation ($VUZI) Q3 EPS loss (-$0.13), in-line with ests; Q3 revs $3.02M vs. est. $3.79M; General and Administrative expense for the three months ended September 30, 2021 was $3.1 million versus $1.6 million for the comparable 2020 period Xperi Holding Corporation ($XPER) 3Q adj EPS $0.53 vs est. $0.34 on res $219.4Mm vs est. $215.4Mm; guides FY revs $870-890Mm vs est. $882.2Mm Zynga ($ZNGA) 4Q EPS ($0.04) vs est. $0.07 on revs $704.7Mm vs est. $666Mm, qtrly bookings $668Mm +6%, average mobile DAUs 38Mm +21%, qtrly avg mobile MAUs 183Mm +120%; sees FY revs $2.78B vs est. $2.81B, sees FY bookings $2.814B